Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171560 | 0.87 | P4HA1 (0.54) | WNT3AQDPRSIGMAR1HTR2CHRH3 | |
| SCHEMBL31701883 | 0.82 | WNT3A (0.42) | WNT3AQDPRSIGMAR1HTR2CCCNT1 | |
| SCHEMBL22047337 | 0.82 | SPR (0.47) | WNT3AHPGDSQDPRCCNT1CDK9 | |
| SCHEMBL5603681 | 0.79 | QDPR (0.61) | QDPRSCN9ASIGMAR1HTR2C | |
| SCHEMBL21454739 | 0.78 | WNT3A (0.41) | WNT3AQDPRSCN9ASIGMAR1HTR2C | |
| SCHEMBL5225955 | 0.77 | HDAC1 (0.51) | — | |
| SCHEMBL29936063 | 0.77 | SIGMAR1 (0.44) | WNT3AQDPRSIGMAR1HTR2CHRH3 | |
| SCHEMBL10068060 | 0.77 | QDPR (0.59) | WNT3AQDPRSIGMAR1HTR2CHRH3 | |
| SCHEMBL171525 | 0.77 | SIGMAR1 (0.44) | WNT3AQDPRSIGMAR1HTR2CHRH3 | |
| Hydrochloric Acid SCHEMBL5223257 | 0.76 | HDAC1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2426120-A1 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | Fujifilm Finechemicals Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | NNMT 2603/4885SMN1; SMN2 4714/4885WNT3A 4254/4885 |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | QDPR, HRH4, HRH2 | NNMT 2752/4885SMN1; SMN2 4779/4885WNT3A 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.